Vertex Pharmaceuticals Incorporated
VRTX
Below: live stock price for Vertex Pharmaceuticals Incorporated (VRTX), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Vertex Pharmaceuticals Incorporated (VRTX) is a Healthcare company based in United States. Operating in Biotechnology, it employs about 6,400 people. Over the past year VRTX traded between 403.16 and 560.25 USD. Trailing P/E sits near 29.11 on a market cap of about 126.58B USD.
- Prev close
- $508.75
- Volume (24h)
- $706.28M
- Market cap
- $126.58B
- Currency
- USD
Score
62/ 100 · Solid
- Value32
- Quality81
- Momentum46
- Growth42
- Risk80
- Dividend50
- Liquidity100
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 500.4789 +0.15%
- +20 bars
- 501.5002 +0.35%
- +60 bars
- 501.8958 +0.43%
- +120 bars
- 501.9103 +0.43%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.0444 USD.
Interpretation
Composite signals look solid. Strength: balance-sheet liquidity with weakness: valuation. Price sits in the middle of the recent range, trend is roughly flat.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value32/100
Value looks weak — driven by P/E (29.11).
P/E:29.11P/B:6.25PEG:1.96 - Quality81/100
Quality looks strong — driven by Gross margin (54.96%).
ROE:23.54%ROA:11.93%Profit margin:35.00%Gross margin:54.96% - Momentum46/100
Momentum looks mixed — driven by 52w change (19.24%).
52w change:19.24% - Growth42/100
Growth looks weak — driven by Revenue growth (12.50%).
Revenue growth:12.50%Earnings growth:8.00% - Risk80/100
Risk looks strong — driven by Debt / equity (9.77).
Beta:0.28Debt / equity:9.77Short interest:2.01% - Dividend50/100
Dividend looks mixed — driven by Dividend yield (0.00%).
Dividend yield:0.00%Payout ratio:0.00% - Liquidity100/100
Liquidity looks strong — driven by Current ratio (3.19).
Current ratio:3.19Quick ratio:2.54
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 250 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 28.7%
- Max drawdown
- -15.2%
- Below period high
- -10.8%
- Best day
- +8.31%
- Worst day
- -4.56%
- Up days
- 49%
- Current streak
- 1 down
- Typical day swing
- 2.5%
- Volume vs average
- +5%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 560.25 high → 465.51 low · 60 bars
- ResistanceFib +161.8% extensionnot reached713.5393 USD+42.78% from current
- ResistanceFib +100% extensionnot reached654.99 USD+31.07% from current
- ResistanceFib +61.8% extensionnot reached618.7993 USD+23.82% from current
- ResistanceFib +27.2% extensionnot reached586.0193 USD+17.26% from current
- ResistanceFib 23.6% retracementtested 3×537.8914 USD+7.63% from current
- ResistanceFib 38.2% retracementtested 15×524.0593 USD+4.87% from current
- ResistanceFib 50% midpointtested 14×512.88 USD+2.63% from current
- ResistanceFib 61.8% retracementNearesttested 8×501.7007 USD+0.39% from current
- Current499.74 USD
- SupportFib 78.6% retracementtested 8×485.7844 USD-2.79% from current
- SupportFib −27.2% extensionnot reached439.7407 USD-12.01% from current
- SupportFib −61.8% extensionnot reached406.9607 USD-18.57% from current
- SupportFib −100% extensionnot reached370.77 USD-25.81% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Financials
- 52w high
- $560.25
- 52w low
- $403.16
- 52w change
- 19.24%
- Day high
- $512.21
- Day low
- $497.49
- P/E (TTM)
- 29.11
- Forward P/E
- 24.86
- PEG
- 1.96
- Price / Book
- 6.25
- Beta (5Y)
- 0.28
- Enterprise value
- 120.79B
- EV / Revenue
- 9.6
- EV / EBITDA
- 23.68
- EPS (TTM)
- $17.17
- Forward EPS
- $20.11
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue (TTM)
- 12.59B
- EBITDA
- 5.1B
- Free cash flow
- 2.63B
- Total cash
- 7.85B
- Total debt
- 1.98B
- Debt / Equity
- 9.77
- Current ratio
- 3.19
- Quick ratio
- 2.54
- Profit margin
- 35.00%
- Gross margin
- 54.96%
- Return on assets
- 11.93%
- Return on equity
- 23.54%
- Shares outstanding
- 253.3M
- Float
- 252.68M
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Analyst & Risk
- Beta (vs S&P 500)
- 0.28
- very stable
- 52-week change
- 19.24%
- Short % of float
- 2.01%
- Short ratio (days)
- 4.39
- Debt / Equity
- 9.77
- very high leverage
- Current ratio
- 3.19
- Quick ratio
- 2.54
- ROE
- 23.54%
- ROA
- 11.93%
- PEG ratio
- 1.96
- fair
- EV / Revenue
- 9.6
- EV / EBITDA
- 23.68
- Revenue growth
- 12.50%
- Earnings growth
- 8.00%
- EBITDA
- 5.1B
- Free cash flow
- 2.63B
- Total cash
- 7.85B
- Total debt
- 1.98B
- Insider holdings
- 0.21%
- Institutional
- 98.22%
Recent rating changes
- 2026-10-08RBC CapitalOutperform → Outperformmain
- 2026-09-28UBSBuy → Buymain
- 2026-08-05Truist SecuritiesBuy → Buymain
- 2026-08-05BarclaysOverweight → Overweightmain
- 2026-08-04TD CowenBuy → Buymain
- 2026-08-04Cantor FitzgeraldOverweight → Overweightmain
- 2026-08-04Canaccord GenuityHold → Holdmain
- 2026-07-13UBSBuy → Buymain
Financial documents
- Corporate Changes & Voting Matters8-K2026-09-01
- Periodic Financial Reports10-Q2026-08-04
- Corporate Changes & Voting Matters8-K2026-08-03
- Corporate Changes & Voting Matters8-K2026-07-07
- Offering RegistrationsS-8 POS2026-05-13
- Periodic Financial Reports10-Q2026-05-05
- Corporate Changes & Voting Matters8-K2026-05-04
- Proxy StatementsDEFA14A2026-04-29
- Proxy StatementsDEFA14A2026-04-02
- A correspondence can be sent as a document with another submission type or can be sent as a separate submissionCORRESP2026-04-01
- Corporate Changes & Voting Matters8-K2026-03-31
- Periodic Financial Reports10-K2026-02-13
Recent news
- What Vertex Pharmaceuticals (VRTX)'s Pancreas Recovery Data Means For ShareholdersSimply Wall St.10h ago
- Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.Motley Fool14h ago
- Vertex (VRTX) Stock May Be 35% Undervalued Despite New ALYFTREK DataSimply Wall St.1d ago
- Vertex Pharmaceuticals (VRTX) Pancreatic Function Data Puts Its Undervalued Narrative In FocusSimply Wall St.1d ago
- Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?Zacks2d ago
- 1 Nasdaq 100 Stock on Our Watchlist and 2 That UnderwhelmStockStory2d ago
- Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key FactsZacks3d ago
- Vortex Energy Corp. Announces Extension of Marketing ProgramGlobeNewswire3d ago
Related
Other assets in this category.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,431 USD-1.27%
- 7203.TToyota Motor Corporation3,075 USD-0.61%
- 9984.TSoftBank Group Corp.4,732 USD-4.29%
- 6758.TSony Group Corporation3,946 USD-0.33%
- 6861.TKeyence Corporation79,950 USD-1.00%
- NVDANVIDIA Corporation214.13 USD-1.43%
- AAPLApple Inc.343.46 USD+0.43%
- GOOGLAlphabet Inc.340.59 USD-2.47%
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.